Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.
Clinical trial details
A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
Identifier
219369
Sponsor
GLAXOSMITHKLINE, SA
Principal Investigator
JAUME CAPDEVILA CASTILLON
Service
Oncology
Study details
Tumor type: RECTUM
Stage: Early/Locally advanced
Main Investigational Agent : Immunotherapy
Phase: II
Randomization: Non-randomized
Molecular details
Biomarker: MSI pos
Biomarker criteria: Mandatory
Prescreening: Local/Central
Additional study population requirements: Participant has a tumor which can be categorized as dMMR or MSI-H by local or central assessment
